emDocs - October 17, 2018 - By Cisewski D
Edited by: Singh M, Alex Koyfman A and Long B
"Last week on Pain Profiles we discussed a feasibility trial assessing the use of intranasal ketamine for pediatric musculoskeletal pain. A few weeks ago I had the pleasure of talking to Dr. Stacy Reynolds regarding her research with intranasal ketamine pediatric analgesia. [Recall: In 2017, Dr. Reynolds was the lead author on a landmark study presented at the SAEM Annual Conference assessing the feasibility of intranasal ketamine use among pediatric patients with extremity injuries. The results of this study provided supporting evidence for a large-scale, multi-center pediatric trial to assess the safety and efficacy of intranasal ketamine among pediatric population with extremity injuries.] The following is a re-print of an SAEM Pulse interview I did with Dr. Reynolds regarding her research, career interests, and advice for future research-driven students and residents interested in following in her footsteps."
*
emDocs - September 19, 2018 - By Cisewski D
Edited by: Singh M, Alex Koyfman A and Long B
"So what’s the upshot?
IN ketamine resulted in an acceptable (tolerable) increase in side effects over IN fentanyl, and neither drug proved more efficacious in pain reduction. Having met each of these threshold criteria, the authors confirm that a larger pediatric trial to assess efficacy and safety of IN ketamine for acute extremity pain management is needed. IN administration is already a well-established technique, and this study is a further step toward a promising opioid-sparing analgesic alternative and delivery for pain management."